These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22190396)

  • 41. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.
    Boyd A; Gozlan J; Maylin S; Delaugerre C; Peytavin G; Girard PM; Zoulim F; Lacombe K
    Hepatology; 2014 Aug; 60(2):497-507. PubMed ID: 24752996
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co-infected patients from Western Africa.
    Boyd A; Moh R; Maylin S; Abdou Chekaraou M; Mahjoub N; Gabillard D; Anglaret X; Eholié SP; Delaugerre C; Danel C; Zoulim F; Lacombe K;
    J Viral Hepat; 2018 Oct; 25(10):1121-1131. PubMed ID: 29660214
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
    Matthews GV; Avihingsanon A; Lewin SR; Amin J; Rerknimitr R; Petcharapirat P; Marks P; Sasadeusz J; Cooper DA; Bowden S; Locarnini S; Ruxrungtham K; Dore GJ
    Hepatology; 2008 Oct; 48(4):1062-9. PubMed ID: 18697216
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of three luminescent immunoassays for hepatitis B virus surface antigen quantification during the natural history of chronic hepatitis B virus infection.
    Cheng XD; Song LW; Fang LL; Yang L; Wu Y; Ge SX; Yuan Q; Zhang J; Xia NS; Hao XK
    Clin Vaccine Immunol; 2014 Nov; 21(11):1521-7. PubMed ID: 25209557
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatitis B and D viruses replication interference: Influence of hepatitis B genotype.
    Madejón A; Romero M; Hernández Á; García-Sánchez A; Sánchez-Carrillo M; Olveira A; García-Samaniego J
    World J Gastroenterol; 2016 Mar; 22(11):3165-74. PubMed ID: 27003993
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence of hepatitis B e antigen among human immunodeficiency virus and hepatitis B virus co-infected patients in Jos, Nigeria.
    Iroezindu MO; Daniyam CA; Agbaji OO; Isa ES; Okeke EN; Imade GE
    J Infect Dev Ctries; 2013 Dec; 7(12):951-9. PubMed ID: 24334942
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological features.
    Morsica G; Ancarani F; Bagaglio S; Maracci M; Cicconi P; Cozzi Lepri A; Antonucci G; Bruno R; Santantonio T; Tacconi L; Baldelli F; Piscopo R; Santoro D; Lazzarin A; D'Arminio Monforte A;
    Infection; 2009 Oct; 37(5):445-9. PubMed ID: 19669092
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Investigation of occult hepatitis B in HIV infected patients].
    Altınbaş A; Ergünay K; Calık Başaran N; Alp A; Turgut D; Hasçelik G; Uzun Ö; Unal S
    Mikrobiyol Bul; 2011 Apr; 45(2):353-8. PubMed ID: 21644079
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV.
    Wursthorn K; Buggisch P; Lutgehetmann M; Zollner B; Petersen J
    Antivir Ther; 2006; 11(5):647-52. PubMed ID: 16964835
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical performance of the novel DiaSorin LIAISON(®) XL murex: HBsAg Quant, HCV-Ab, HIV-Ab/Ag assays.
    Krawczyk A; Hintze C; Ackermann J; Goitowski B; Trippler M; Grüner N; Neumann-Fraune M; Verheyen J; Fiedler M
    J Clin Virol; 2014 Jan; 59(1):44-9. PubMed ID: 24268764
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Persistent HBV replication and serological response during up to 15 years of tenofovir-based antiretroviral therapy in HIV/HBV-coinfected patients: a multicentre prospective cohort study.
    Dezanet LNC; Miailhes P; Lascoux-Combe C; Chas J; Maylin S; Gabassi A; Rougier H; Delaugerre C; Lacombe K; Boyd A
    J Antimicrob Chemother; 2021 Oct; 76(11):3009-3019. PubMed ID: 34458919
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.
    Zoulim F; Carosi G; Greenbloom S; Mazur W; Nguyen T; Jeffers L; Brunetto M; Yu S; Llamoso C
    J Hepatol; 2015 Jan; 62(1):56-63. PubMed ID: 25176615
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Lumipulse G HBsAg-Quant assay for screening and quantification of the hepatitis B surface antigen.
    Yang R; Song G; Guan W; Wang Q; Liu Y; Wei L
    J Virol Methods; 2016 Feb; 228():39-47. PubMed ID: 26615803
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of performance characteristics of hepatitis B e antigen serologic assays.
    Mixson-Hayden T; Purdy MA; Ganova-Raeva L; McGovern D; Forbi JC; Kamili S
    J Clin Virol; 2018 Dec; 109():22-28. PubMed ID: 30388663
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A predictive value of quantitative HBsAg for serum HBV DNA level among HBeAg-positive pregnant women.
    Sun KX; Li J; Zhu FC; Liu JX; Li RC; Zhai XJ; Li YP; Chang ZJ; Nie JJ; Zhuang H
    Vaccine; 2012 Aug; 30(36):5335-40. PubMed ID: 22749833
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Coexistence of circulating HBsAg and anti-HBs antibodies in chronic hepatitis B carriers is not a simple analytical artifact and does not influence HBsAg quantification.
    Pancher M; Désiré N; Ngo Y; Akhavan S; Pallier C; Poynard T; Thibault V
    J Clin Virol; 2015 Jan; 62():32-7. PubMed ID: 25542467
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort.
    Kang M; Hollabaugh K; Pham V; Koletar SL; Wu K; Smurzynski M; Aberg JA
    J Acquir Immune Defic Syndr; 2014 Jun; 66(2):172-80. PubMed ID: 24694927
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients.
    Strassl R; Reiberger T; Honsig C; Payer BA; Mandorfer M; Grabmeier-Pfistershammer K; Rieger A; Kundi M; Grundtner P; Peck-Radosavljevic M; Popow-Kraupp T
    J Viral Hepat; 2014 Jul; 21(7):508-16. PubMed ID: 24112778
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevalence, risk factors and genotypes of hepatitis B infection among HIV-infected patients in the State of MS, Central Brazil.
    Freitas SZ; Soares CC; Tanaka TS; Lindenberg AS; Teles SA; Torres MS; Mello FC; Mendes-Corrêa MC; Savassi-Ribas F; Motta-Castro AR
    Braz J Infect Dis; 2014; 18(5):473-80. PubMed ID: 24662138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.